Significant Cost Reduction Achieved
The company reduced its headcount by 60% and successfully lowered its burn rate to under $1 million per month, maintaining this target into the third quarter.
Strategic Transition to U.S. Operations
Numinus transitioned out of Canadian clinic operations, focusing on U.S.-based clinics. New client appointments increased by 24% and ketamine and SPRAVATO appointments rose by 15% in Q3.
Proposed Acquisition of MedBright AI
The acquisition of MedBright AI aims to enhance clinic efficiency with AI solutions, providing infrastructure in a SaaS model, and is seen as a significant opportunity for growth.
Increased Revenue from Cedar Clinical Research
Revenue from Cedar Clinical Research increased by 10.7% to $0.8 million in Q3 due to a new clinical trial, showing a positive trend despite other declines.
Growth in Practitioner Training Program
The program grew from 400 learners in Q4 2023 to over 1,650 by May 31, 2024, indicating strong interest and uptake.